Results 291 to 300 of about 2,311,673 (316)
Some of the next articles are maybe not open access.
Best Practice & Research Clinical Rheumatology, 2019
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti ...
L. Sammaritano
semanticscholar +3 more sources
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies that include the lupus anticoagulant, or moderate-high titer anticardiolipin, or anti ...
L. Sammaritano
semanticscholar +3 more sources
Current Opinion in Rheumatology, 2006
To review the recently published studies that can guide physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.Two recent prospective randomized controlled trials of two intensities of warfarin concluded that both moderate and high-intensity anticoagulation are similarly protective in antiphospholipid syndrome ...
Doruk, Erkan, Michael D, Lockshin
openaire +2 more sources
To review the recently published studies that can guide physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.Two recent prospective randomized controlled trials of two intensities of warfarin concluded that both moderate and high-intensity anticoagulation are similarly protective in antiphospholipid syndrome ...
Doruk, Erkan, Michael D, Lockshin
openaire +2 more sources
Hematology, 2013
Abstract The antiphospholipid syndrome (APS) is defined by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPLs). Catastrophic APS is the most severe form of APS, which is associated with rapid development of microvascular thrombosis resulting in multiorgan ...
openaire +2 more sources
Abstract The antiphospholipid syndrome (APS) is defined by venous or arterial thrombosis and/or pregnancy morbidity in patients with persistent presence of antiphospholipid antibodies (aPLs). Catastrophic APS is the most severe form of APS, which is associated with rapid development of microvascular thrombosis resulting in multiorgan ...
openaire +2 more sources
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two‐year outcomes after the study closure
Journal of Thrombosis and Haemostasis, 2020Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open‐label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and ...
V. Pengo +17 more
semanticscholar +1 more source
Progress in Cardiovascular Diseases, 2009
The antiphospholipid syndrome (APS) is an autoimmune systemic disease that is diagnosed when there is vascular thrombosis and/or pregnancy morbidity occurring with persistently positive antiphospholipid antibodies (aPL) (lupus anticoagulant test, anticardiolipin antibodies, and/or anti-beta(2)-glycoprotein I antibodies).
Diane, George, Doruk, Erkan
openaire +2 more sources
The antiphospholipid syndrome (APS) is an autoimmune systemic disease that is diagnosed when there is vascular thrombosis and/or pregnancy morbidity occurring with persistently positive antiphospholipid antibodies (aPL) (lupus anticoagulant test, anticardiolipin antibodies, and/or anti-beta(2)-glycoprotein I antibodies).
Diane, George, Doruk, Erkan
openaire +2 more sources
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome
Annals of Internal Medicine, 2019Antiphospholipid antibody syndrome (APS) is an acquired thrombophilic disorder in which vascular thrombosis (venous or arterial) and pregnancy losses may occur in the presence of persistent antiphospholipid antibodies (aPLs) (14).
J. Ordi‐Ros +10 more
semanticscholar +1 more source
Lupus, 2020
The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019.
R. Cervera +3 more
semanticscholar +1 more source
The Task Force on Catastrophic Antiphospholipid Syndrome (CAPS) met again on occasion of the 16th International Congress on Antiphospholipid Antibodies (aPL) that was held in Manchester, England, in September 2019.
R. Cervera +3 more
semanticscholar +1 more source
Antiphospholipid antibodies and antiphospholipid syndrome
Current Opinion in Rheumatology, 1995More than a decade has gone by since the detailed clinical description of antiphospholipid syndrome (APS). Thrombosis, the main complication of the syndrome, can affect vessels of all sizes; the consistent histopathologic lesion is a bland thrombus without inflammation.
M A, Khamashta, G R, Hughes
openaire +2 more sources
Pediatric Antiphospholipid Syndrome
Current Rheumatology Reports, 2015Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by vascular thromboses associated with persistently positive antiphospholipid antibodies. There is currently a paucity of data (incidence, prevalence, thrombosis risk, and effective treatment) in pediatric APS.
Cassyanne L, Aguiar +3 more
openaire +2 more sources
Antiphospholipid Antibody Syndrome
Current Opinion in Ophthalmology, 2012Antiphospholipid antibody (APLA) syndrome (APS) is a heterogeneous disorder defined by the finding of persistent APLA in patients with arterial or venous thrombosis or pregnancy morbidity. APS manifestations range from deep vein thrombosis to stroke and even rapid multiorgan failure (the rare catastrophic APS).
Zambon M., Cappelli D., Berlot G.
openaire +4 more sources